2023
6-Month Real World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry
Lebwohl M, Strober B, Schrader A, Li A, Eckmann T, Zhu B, Malatestinic W, Birt J, Feely M, Blauvelt A. 6-Month Real World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. SKIN The Journal Of Cutaneous Medicine 2023, 7: s232. DOI: 10.25251/skin.7.supp.232.Peer-Reviewed Original Research43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
Strober B, Ferris L, Duffin K, Janak J, Sima A, Eckmann T, Patel M, Photowala H, Garg V, Armstrong A. 43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry. Journal Of The American Academy Of Dermatology 2023, 89: ab189. DOI: 10.1016/j.jaad.2023.07.756.Peer-Reviewed Original Research44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
Armstrong A, Ferris L, Duffin K, Janak J, Sima A, Eckmann T, Photowala H, Patel M, Garg V, Strober B. 44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry. Journal Of The American Academy Of Dermatology 2023, 89: ab62. DOI: 10.1016/j.jaad.2023.07.251.Peer-Reviewed Original Research
2022
33933 Relationship between skin involvement and disease burden in patients with mild to moderate plaque psoriasis: Real-world findings From CorEvitas’ Psoriasis Registry
Ogdie A, Strober B, Lebwohl M. 33933 Relationship between skin involvement and disease burden in patients with mild to moderate plaque psoriasis: Real-world findings From CorEvitas’ Psoriasis Registry. Journal Of The American Academy Of Dermatology 2022, 87: ab103. DOI: 10.1016/j.jaad.2022.06.444.Peer-Reviewed Original Research34940 Real-world patient-reported outcomes with risankizumab in patients with moderate to severe psoriasis from the CorEvitas Psoriasis Registry
Strober B, Ferris L, Duffin K. 34940 Real-world patient-reported outcomes with risankizumab in patients with moderate to severe psoriasis from the CorEvitas Psoriasis Registry. Journal Of The American Academy Of Dermatology 2022, 87: ab101. DOI: 10.1016/j.jaad.2022.06.438.Peer-Reviewed Original Research34820 Real-world treat-to-target skin clearance with risankizumab in patients with moderate to severe psoriasis from the CorEvitas Psoriasis Registry
Armstrong A, Ferris L, Duffin K, Janak J, Sima A, Eckmann T, Patel M, Photowala H, Garg V, Strober B. 34820 Real-world treat-to-target skin clearance with risankizumab in patients with moderate to severe psoriasis from the CorEvitas Psoriasis Registry. Journal Of The American Academy Of Dermatology 2022, 87: ab200. DOI: 10.1016/j.jaad.2022.06.833.Peer-Reviewed Original ResearchProspective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registry
Ogdie A, Harrison R, McLean R, Lin T, Lebwohl M, Strober B, Zhuo J, Patel V, Mease P. Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registry. Journal Of The American Academy Of Dermatology 2022, 87: 1303-1311. PMID: 35987397, DOI: 10.1016/j.jaad.2022.07.060.Peer-Reviewed Original ResearchConceptsPsoriasis Epidemiology Screening ToolBody mass indexProspective cohort studyPsoriasis RegistryCohort studyRheumatic Disease Comorbidity IndexOnset of PsAPatient-reported fatigueDevelopment of PsALogistic regression modelsComorbidity indexPsoriatic arthritisMass indexRisk model developmentArthritis riskPatientsScreening toolAlcohol usePSAUnique predictive modelsWork statusMisclassification biasCharacteristic curvePsoriasisRegistry
2021
25031 Greater disease burden associated with palmoplantar pustulosis versus plaque psoriasis: Real-world evidence from the North American–based Corrona Psoriasis Registry
Lebwohl M, Kotowsky N, Medeiros R, Foster N, Janak J, Valdecantos W, Flack M, Golembesky A, Strober B. 25031 Greater disease burden associated with palmoplantar pustulosis versus plaque psoriasis: Real-world evidence from the North American–based Corrona Psoriasis Registry. Journal Of The American Academy Of Dermatology 2021, 85: ab4. DOI: 10.1016/j.jaad.2021.06.042.Peer-Reviewed Original Research26588 Patient-reported outcomes from a large, North American-based cohort, highlight a greater disease burden for generalized pustular psoriasis vs plaque psoriasis: Real-world evidence from the Corrona Psoriasis Registry
Strober B, Kotowsky N, Medeiros R, Foster N, Janak J, Valdecantos W, Flack M, Golembesky A, Lebwohl M. 26588 Patient-reported outcomes from a large, North American-based cohort, highlight a greater disease burden for generalized pustular psoriasis vs plaque psoriasis: Real-world evidence from the Corrona Psoriasis Registry. Journal Of The American Academy Of Dermatology 2021, 85: ab108. DOI: 10.1016/j.jaad.2021.06.451.Peer-Reviewed Original Research26698 Characteristics and disease burden in patients with mild to moderate vs severe plaque psoriasis in real-world settings: Results from the Corrona Psoriasis Registry
Strober B, Cronin A, Lin T, O’Brien J, Emeanuru K, Kang H, Gomez N, Khilfeh I, Lebwohl M. 26698 Characteristics and disease burden in patients with mild to moderate vs severe plaque psoriasis in real-world settings: Results from the Corrona Psoriasis Registry. Journal Of The American Academy Of Dermatology 2021, 85: ab113. DOI: 10.1016/j.jaad.2021.06.471.Peer-Reviewed Original ResearchDrug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry
Lockshin B, Cronin A, Harrison R, McLean R, Anatale‐Tardiff L, Burge R, Zhu B, Malatestinic W, Atiya B, Murage M, Gallo G, Strober B, Van Voorhees A. Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry. Dermatologic Therapy 2021, 34: e14808. PMID: 33491259, PMCID: PMC8047872, DOI: 10.1111/dth.14808.Peer-Reviewed Original ResearchConceptsCorrona Psoriasis RegistryIL-17 inhibitorsIL-17iTNF inhibitorsReal-world patientsDrug survivalHazard ratioPsoriasis RegistryDrug discontinuationDrug initiationLower riskBiologic experienceIxekizumab groupsPsO patientsSevere PsONaïve patientsMean ageIxekizumabPatientsReal-world settingDiscontinuationPsoriasisSurvivalRegistryInhibitors
2020
16533 Real-world characteristics of patients with psoriasis initiating brodalumab: Findings from the Corrona Psoriasis Registry
Armstrong A, Strober B, Drew S, Cronin A, Jacobson A. 16533 Real-world characteristics of patients with psoriasis initiating brodalumab: Findings from the Corrona Psoriasis Registry. Journal Of The American Academy Of Dermatology 2020, 83: ab181. DOI: 10.1016/j.jaad.2020.06.811.Peer-Reviewed Original Research15457 Secukinumab significantly improves clinical and patient-reported outcomes up to 18 months of follow-up: Real-world evidence from a US psoriasis registry
Bagel J, Behl A, Litman H, Medeiros R, Guo N, Lebwohl M, Strober B. 15457 Secukinumab significantly improves clinical and patient-reported outcomes up to 18 months of follow-up: Real-world evidence from a US psoriasis registry. Journal Of The American Academy Of Dermatology 2020, 83: ab152. DOI: 10.1016/j.jaad.2020.06.697.Peer-Reviewed Original ResearchCharacterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry
Van Voorhees A, Mason M, Harrold L, Guo N, Guana A, Tian H, Herrera V, Strober B. Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry. Journal Of Dermatological Treatment 2020, 32: 907-915. PMID: 32027197, DOI: 10.1080/09546634.2020.1720586.Peer-Reviewed Original ResearchConceptsCorrona Psoriasis RegistrySevere psoriasisPsoriasis RegistryInsufficient respondersPsoriasis body surface areaBody surface areaLogistic regression modelingReal-world studyBiologic therapyPatient demographicsUS patientsBiologic treatmentDisease characteristicsInadequate responseInsufficient responsePatientsPsoriasisDecreased likelihoodRespondersRegistryVisitsRegression modelingEnrollmentFollowOutcomes
2019
US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry
Strober B, Germino R, Guana A, Greenberg J, Litman H, Guo N, Lebwohl M. US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. Journal Of Dermatological Treatment 2019, 31: 333-341. PMID: 31035822, DOI: 10.1080/09546634.2019.1603361.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesCorrona Psoriasis RegistryGlobal assessment scoreBody surface areaReal-world effectivenessPsoriasis RegistryReal-world studySecukinumab treatmentDisease severityInvestigator's Global Assessment scoreMajority of patientsTreatment of psoriasisQuality of lifeEligible patientsSecukinumabPatientsSignificant improvementFollowAssessment scoresRegistryVisitsWork productivityPsoriasisDaily activitiesTreatment
2018
Systematic review of the real‐world evidence of adalimumab safety in psoriasis registries
Strober B, Crowley J, Langley R, Gordon K, Menter A, Leonardi C, Arikan D, Valdecantos W. Systematic review of the real‐world evidence of adalimumab safety in psoriasis registries. Journal Of The European Academy Of Dermatology And Venereology 2018, 32: 2126-2133. PMID: 30067882, DOI: 10.1111/jdv.15203.Peer-Reviewed Original ResearchConceptsMajor cardiac eventsAdverse eventsPsoriasis RegistryReal-world evidenceAdalimumab safetySerious AEsAdult patientsCardiac eventsClinical studiesSafety dataLong-term safety profileCardiovascular-related eventsSerious adverse eventsSerious cardiovascular eventsReal-world safetyLong-term safetyRate of infectionEnglish language manuscriptsCardiovascular eventsSafety profileSerious infectionsAdalimumabClinical practiceEligible papersRegistry
2017
Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, Goyal K, Lawson F, Langholff W, Hopkins L, Fakharzadeh S, Srivastava B, Menter A. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal Of The American Academy Of Dermatology 2017, 78: 70-80. PMID: 29102053, DOI: 10.1016/j.jaad.2017.08.051.Peer-Reviewed Original ResearchConceptsImpact of treatmentPsoriasis Longitudinal AssessmentConventional therapyAdverse eventsDepressive symptomsIncidence rateLongitudinal assessmentConventional systemic therapiesSevere psoriasisBiologic therapySystemic therapyLower incidenceStudy populationPatientsTherapySymptomsPsoriasisRegistryBiologicsPhototherapyDepressionIncidenceMultivariate modelingRiskTreatment